Considering the pivotal role of FGF1 and FGFR2 in iCCA oncogenesis and progression, we hypothesized that RORγ antagonists may attenuate iCCA malignancy via FGF/FGFR signaling. Here, FGFR2 is linked to infantile convulsions and choreoathetosis.